Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pre-existing influenza-specific nasal IgA or nasal viral infection does not affect live attenuated influenza vaccine immunogenicity in children.
Cole ME, Kundu R, Abdulla AF, Andrews N, Hoschler K, Southern J, Jackson D, Miller E, Zambon M, Turner PJ, Tregoning JS. Cole ME, et al. Among authors: hoschler k. Clin Exp Immunol. 2021 Apr;204(1):125-133. doi: 10.1111/cei.13564. Epub 2021 Jan 13. Clin Exp Immunol. 2021. PMID: 33314126 Free PMC article. Clinical Trial.
Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
Nolan TM, Richmond PC, Skeljo MV, Pearce G, Hartel G, Formica NT, Höschler K, Bennet J, Ryan D, Papanaoum K, Basser RL, Zambon MC. Nolan TM, et al. Among authors: hoschler k. Vaccine. 2008 Aug 5;26(33):4160-7. doi: 10.1016/j.vaccine.2008.05.077. Epub 2008 Jun 13. Vaccine. 2008. PMID: 18599164 Clinical Trial.
A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine.
Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, Höschler K, Saville M, Vogel FR, Barclay W, Donatelli I, Zambon M, Wood J, Haaheim LR. Cox RJ, et al. Among authors: hoschler k. Vaccine. 2009 Mar 18;27(13):1889-97. doi: 10.1016/j.vaccine.2009.01.116. Epub 2009 Feb 2. Vaccine. 2009. PMID: 19368768 Clinical Trial.
A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies.
Temperton NJ, Hoschler K, Major D, Nicolson C, Manvell R, Hien VM, Ha do Q, de Jong M, Zambon M, Takeuchi Y, Weiss RA. Temperton NJ, et al. Among authors: hoschler k. Influenza Other Respir Viruses. 2007 May;1(3):105-12. doi: 10.1111/j.1750-2659.2007.00016.x. Influenza Other Respir Viruses. 2007. PMID: 19453415 Free PMC article.
Reproducibility of serologic assays for influenza virus A (H5N1).
Stephenson I, Heath A, Major D, Newman RW, Hoschler K, Junzi W, Katz JM, Weir JP, Zambon MC, Wood JM. Stephenson I, et al. Among authors: hoschler k. Emerg Infect Dis. 2009 Aug;15(8):1252-9. doi: 10.3201/eid1508.081754. Emerg Infect Dis. 2009. PMID: 19751587 Free PMC article.
Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.
Waddington CS, Walker WT, Oeser C, Reiner A, John T, Wilkins S, Casey M, Eccleston PE, Allen RJ, Okike I, Ladhani S, Sheasby E, Hoschler K, Andrews N, Waight P, Collinson AC, Heath PT, Finn A, Faust SN, Snape MD, Miller E, Pollard AJ. Waddington CS, et al. Among authors: hoschler k. BMJ. 2010 May 27;340:c2649. doi: 10.1136/bmj.c2649. BMJ. 2010. PMID: 20508026 Free PMC article. Clinical Trial.
122 results